1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b...1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b。3背景用于监测免疫检查点抑制剂治疗反应的生物标志物很少,尤其是可用于多种癌症类型的生物标志物。展开更多
1文献来源Paik PK,Felip E,Veillon R,et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med,2020,383(10):931-943.2证据水平2b。3背景约3%~4%非小细胞肺癌(non-small-cell lung can...1文献来源Paik PK,Felip E,Veillon R,et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med,2020,383(10):931-943.2证据水平2b。3背景约3%~4%非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者具有MET 14外显子跳读突变。Tepotinib是高选择性口服MET抑制剂,既往研究表明,tepotinib在MET驱动的肿瘤患者中已显示出令人鼓舞的临床活性。展开更多
文摘1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b。3背景用于监测免疫检查点抑制剂治疗反应的生物标志物很少,尤其是可用于多种癌症类型的生物标志物。
文摘1文献来源Paik PK,Felip E,Veillon R,et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med,2020,383(10):931-943.2证据水平2b。3背景约3%~4%非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者具有MET 14外显子跳读突变。Tepotinib是高选择性口服MET抑制剂,既往研究表明,tepotinib在MET驱动的肿瘤患者中已显示出令人鼓舞的临床活性。